ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2227

Low Dosage with Escalating Dosage of Infliximab in Psoriatic Arthritis Gives the Same Treatment Results as Standard Dosage of Adalimumab or Etanercept: Results From the Nationwide Registry ICEBIO

Bjorn Gudbjornsson1 and Niels Steen Krogh2, 1Department of Rheumatology, Center for Rheumatology Research (ICEBIO), Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland, 2ZiteLab ApS, Copenhagen, Denmark

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Adalimumab, etanercept, infliximab, psoriatic arthritis and treatment

  • Tweet
  • Email
  • Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose: To explore differences in response to low dosage (2.3mg/kg) regimen of infliximab with possible escalating dosage in comparison to standard dosage of etanercept and adalimumab over time in patients with psoriatic arthritis (PsA).

Methods: Patients with PsA who were all biologically naïve and initiating anti-TNF-α therapy were selected from the ICEBIO registry which is based on the DANBIO IT platform. Demographics and clinical differences at baseline, including DAS-28CRP, were compared in four treatment groups: 1) Those who responded to low dosage of infliximab (< 4 mg/kg), 2) those who needed to increase the dosage of infliximab above 4 mg/kg, and those who received a standard dosage of 3) etanercept or 4) adalimumab. Follow-up data at 26 ± 6 and 52 ± 6 weeks and on the last visit (at least 13 weeks after the initiation of the treatment) were also compared. The Kruskal-Wallis rank sum test was used for comparison of the groups and the Wilcoxon test was used to compare the two infliximab dosage regimens.

Results: 185 patients, 113 women and 72 men, were identified; 84 patients received infliximab, 66 etanercept and 35 adalinmumab. Only 19% of the patients (16/84) treated with infliximab needed to escalate their dosage to exceed 4 mg/kg; thus those still on a low dosage regimen had a mean dosage of infliximab 2.9 mg/kg, but those who had escalated their dosage had a mean dosage of 4.5 mg/kg, i.e. still under the recommended 5 mg/kg. At baseline those who continued low dosage infliximab had a shorter disease duration (8 vs. 10 years), while those who needed to increase their dosage of infliximab had a higher CRP (10.4 vs. 17.2 g/L), but neither value reached significant differences. No significant differences were observed at baseline in respect to numbers of swollen or tender joints, HAQ, VAS pain, VAS fatigue or DAS28-CRP values. A similar treatment response was observed in all four treatment groups on follow-up.

Conclusion: In respect to treatment effects a low dosage of infliximab, with starting dosage of 2.3mg/kg with possible escalating dosage, is acceptable for the majority of psoriatic arthritis patients who are in need of biological treatment. This “low dosage treatment regimen” with infliximab significantly reduces the burden of drug cost for the society.

*ICEBIO: Erlendsson K, Geirsson AJ, Grondal G, Jonsson H, Jonsdottir T, Ludviksson BR, Steinsson K, Tomasson G, Valtysdottir S, Vikingsson A.


Disclosure:

B. Gudbjornsson,
None;

N. S. Krogh,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/low-dosage-with-escalating-dosage-of-infliximab-in-psoriatic-arthritis-gives-the-same-treatment-results-as-standard-dosage-of-adalimumab-or-etanercept-results-from-the-nationwide-registry-icebio/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology